National Cancer Institute, Bethesda, Maryland.
Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3.
Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. .
鲁卡帕利，一种聚 ADP 核糖聚合酶抑制剂（PARPi），最近被批准用于治疗高级别浆液性卵巢癌（HGSOC）。它现在是三种已批准用于复发性卵巢癌的 PARPi 之一，这一类药物改变了 HGSOC 的治疗格局和结果。
